<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Galderma Group Ag — News on 6ix</title>
<link>https://6ix.com/company/galderma-group-n</link>
<description>Latest news and press releases for Galderma Group Ag on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 22 May 2026 16:25:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/galderma-group-n" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68361af578dffbe2df13efc3.webp</url>
<title>Galderma Group Ag</title>
<link>https://6ix.com/company/galderma-group-n</link>
</image>
<item>
<title>Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch</title>
<link>https://6ix.com/company/galderma-group-n/news/galderma-receives-us-fda-approval-for-differinr-epiduor-acne-gel-prescription-to-otc-switch</link>
<guid isPermaLink="true">https://6ix.com/company/galderma-group-n/news/galderma-receives-us-fda-approval-for-differinr-epiduor-acne-gel-prescription-to-otc-switch</guid>
<pubDate>Fri, 22 May 2026 16:25:00 GMT</pubDate>
<description>ZUG, Switzerland, May 22, 2026--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care.</description>
</item>
<item>
<title>Galderma Reports Strong Start to the Year, Delivering First Quarter 2026 Net Sales of 1.473 Billion USD, Growing 25.5% at Constant Currency</title>
<link>https://6ix.com/company/galderma-group-n/news/galderma-reports-strong-start-to-the-year-delivering-first-quarter-2026-net-sales-of-1473-billion-usd-growing-255percent-at-constant-currency</link>
<guid isPermaLink="true">https://6ix.com/company/galderma-group-n/news/galderma-reports-strong-start-to-the-year-delivering-first-quarter-2026-net-sales-of-1473-billion-usd-growing-255percent-at-constant-currency</guid>
<pubDate>Thu, 23 Apr 2026 05:00:00 GMT</pubDate>
<description>ZUG, Switzerland, April 23, 2026--Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first quarter of 2026.</description>
</item>
<item>
<title>Galderma Shareholders Approve All Annual General Meeting Proposals</title>
<link>https://6ix.com/company/galderma-group-n/news/galderma-shareholders-approve-all-annual-general-meeting-proposals</link>
<guid isPermaLink="true">https://6ix.com/company/galderma-group-n/news/galderma-shareholders-approve-all-annual-general-meeting-proposals</guid>
<pubDate>Wed, 22 Apr 2026 15:45:00 GMT</pubDate>
<description>ZUG, Switzerland, April 22, 2026--Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, announced that shareholders approved all proposals put forward by the Board of Directors at its Annual General Meeting (AGM), held earlier today via live webcast. This includes the payment of a gross dividend of 0.35 CHF per dividend-bearing share1, to be distributed out of reserves from capital contributions.</description>
</item>
<item>
<title>Galderma Launches New Alastin Regenerating Skin Nectar with TriHex+™, Powered by Its Next-Generation TriHex Technology® Regenerative Platform</title>
<link>https://6ix.com/company/galderma-group-n/news/galderma-launches-new-alastin-regenerating-skin-nectar-with-trihextm-powered-by-its-next-generation-trihex-technologyr-regenerative-platform</link>
<guid isPermaLink="true">https://6ix.com/company/galderma-group-n/news/galderma-launches-new-alastin-regenerating-skin-nectar-with-trihextm-powered-by-its-next-generation-trihex-technologyr-regenerative-platform</guid>
<pubDate>Thu, 16 Apr 2026 05:00:00 GMT</pubDate>
<description>ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the launch of Regenerating Skin Nectar with </description>
</item>
<item>
<title>Interim Data From Two Ongoing Investigator-initiated Trials Highlight the Role of Sculptra® and Restylane® in Addressing Aesthetic Changes Associated With Weight Loss Medications and Menopause</title>
<link>https://6ix.com/company/galderma-group-n/news/interim-data-from-two-ongoing-investigator-initiated-trials-highlight-the-role-of-sculptrar-and-restylaner-in-addressing-aesthetic-changes-associated-with-weight-loss-medications-and-menopause</link>
<guid isPermaLink="true">https://6ix.com/company/galderma-group-n/news/interim-data-from-two-ongoing-investigator-initiated-trials-highlight-the-role-of-sculptrar-and-restylaner-in-addressing-aesthetic-changes-associated-with-weight-loss-medications-and-menopause</guid>
<pubDate>Thu, 09 Apr 2026 05:00:00 GMT</pubDate>
<description>ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today welcomes new data from two IITs, demonstrating the pow</description>
</item>
<item>
<title>Galderma Publishes Invitation and Agenda for Its 2026 Annual General Meeting</title>
<link>https://6ix.com/company/galderma-group-n/news/galderma-publishes-invitation-and-agenda-for-its-2026-annual-general-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/galderma-group-n/news/galderma-publishes-invitation-and-agenda-for-its-2026-annual-general-meeting</guid>
<pubDate>Fri, 20 Mar 2026 05:55:00 GMT</pubDate>
<description>ZUG, Switzerland, March 20, 2026--Galderma Group AG (SIX: GALD), the pure-play dermatology category leader, today published the invitation and agenda for its 2026 Annual General Meeting (AGM), which will be held virtually on April 22, 2026, at 3:00pm CEST.</description>
</item>
<item>
<title>EQT exits Galderma Group AG in full via largest sponsor-backed block trade ever</title>
<link>https://6ix.com/company/galderma-group-n/news/eqt-exits-galderma-group-ag-in-full-via-largest-sponsor-backed-block-trade-ever-2</link>
<guid isPermaLink="true">https://6ix.com/company/galderma-group-n/news/eqt-exits-galderma-group-ag-in-full-via-largest-sponsor-backed-block-trade-ever-2</guid>
<pubDate>Fri, 13 Mar 2026 18:17:00 GMT</pubDate>
<description>Sunshine SwissCo GmbH, an affiliate of the EQT VIII fund ("EQT VIII"), together with other selling shareholders, is pleased to announce the completion of the placement of c. 34.0 million shares (the "Shares") in Galderma Group AG (SIX: GALD) ("Galderma") for aggregate gross proceeds of c. CHF 4.9 billion via an accelerated bookbuilding process (the "Placement"). As part of the Placement, EQT VIII received gross proceeds of c. CHF 1.3 billion.</description>
</item>
<item>
<title>Galderma Buys Back Shares Worth CHF 232 Million in the Context of Accelerated Bookbuild Offering</title>
<link>https://6ix.com/company/galderma-group-n/news/galderma-buys-back-shares-worth-chf-232-million-in-the-context-of-accelerated-bookbuild-offering</link>
<guid isPermaLink="true">https://6ix.com/company/galderma-group-n/news/galderma-buys-back-shares-worth-chf-232-million-in-the-context-of-accelerated-bookbuild-offering</guid>
<pubDate>Wed, 11 Mar 2026 06:00:00 GMT</pubDate>
<description>ZUG, Switzerland, March 11, 2026--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it has agreed to repurchase 1.6 million shares at a price of CHF 143.75 per share for a total consideration of CHF 232 million in the context of the accelerated bookbuild offering ("ABO") of Galderma shares by Sunshine SwissCo GmbH ("EQT"), Abu Dhabi Investment Authority (Private Equities Department) and Auba Investment Pte. Ltd. (all together the "Selling Shareholders") launch</description>
</item>
<item>
<title>Galderma Introduces Cetaphil AM/PM Antioxidant Serums, a New Science-Driven Defense and Recovery System for Sensitive Skin</title>
<link>https://6ix.com/company/galderma-group-n/news/galderma-introduces-cetaphil-ampm-antioxidant-serums-a-new-science-driven-defense-and-recovery-system-for-sensitive-skin</link>
<guid isPermaLink="true">https://6ix.com/company/galderma-group-n/news/galderma-introduces-cetaphil-ampm-antioxidant-serums-a-new-science-driven-defense-and-recovery-system-for-sensitive-skin</guid>
<pubDate>Mon, 09 Mar 2026 06:00:00 GMT</pubDate>
<description>ZUG, Switzerland, March 09, 2026--Galderma (SIX: GALD) today announced Cetaphil, the dermatologist-recommended brand trusted by millions with sensitive skin, is launching its new Cetaphil AM/PM Antioxidant Serums, a breakthrough daily system clinically designed to defend skin by day and support accelerated repair by night for sensitive, stressed skin.</description>
</item>
<item>
<title>Galderma Delivers Record 2025 Results With Net Sales of 5.207 Billion USD, up 17.7% at Constant Currency1, and Core EBITDA2 of 1.211 billion USD, Growing 18.9% at Constant Currency</title>
<link>https://6ix.com/company/galderma-group-n/news/galderma-delivers-record-2025-results-with-net-sales-of-5207-billion-usd-up-177percent-at-constant-currency1-and-core-ebitda2-of-1211-billion-usd-growing-189percent-at-constant-currency</link>
<guid isPermaLink="true">https://6ix.com/company/galderma-group-n/news/galderma-delivers-record-2025-results-with-net-sales-of-5207-billion-usd-up-177percent-at-constant-currency1-and-core-ebitda2-of-1211-billion-usd-growing-189percent-at-constant-currency</guid>
<pubDate>Thu, 05 Mar 2026 06:00:00 GMT</pubDate>
<description>ZUG, Switzerland, March 05, 2026--Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025.</description>
</item>
<item>
<title>Galderma’s Nemluvio® (nemolizumab) Demonstrates Long-Term Disease Control in Prurigo Nodularis up to Three Years</title>
<link>https://6ix.com/company/galderma-group-n/news/galdermas-nemluvior-nemolizumab-demonstrates-long-term-disease-control-in-prurigo-nodularis-up-to-three-years</link>
<guid isPermaLink="true">https://6ix.com/company/galderma-group-n/news/galdermas-nemluvior-nemolizumab-demonstrates-long-term-disease-control-in-prurigo-nodularis-up-to-three-years</guid>
<pubDate>Fri, 27 Feb 2026 06:00:00 GMT</pubDate>
<description>ZUG, Switzerland, February 27, 2026--Galderma (SIX: GALD) today announced new data from the OLYMPIA open-label extension study investigating the long-term safety and efficacy of Nemluvio in moderate-to-severe prurigo nodularis.1 Results showed that Nemluvio maintained long-term disease control and a well-tolerated safety profile, with clinically meaningful improvements in itch intensity, skin lesions and quality of life up to three years.1 Results will be presented at 2026 Winter Clinical Miami</description>
</item>
<item>
<title>Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics</title>
<link>https://6ix.com/company/galderma-group-n/news/galderma-announces-triple-approval-of-new-state-of-the-art-restylaner-syringe-in-the-eu-the-us-and-canada-reaffirming-the-companys-position-at-the-forefront-of-injectable-aesthetics</link>
<guid isPermaLink="true">https://6ix.com/company/galderma-group-n/news/galderma-announces-triple-approval-of-new-state-of-the-art-restylaner-syringe-in-the-eu-the-us-and-canada-reaffirming-the-companys-position-at-the-forefront-of-injectable-aesthetics</guid>
<pubDate>Wed, 25 Feb 2026 06:00:00 GMT</pubDate>
<description>ZUG, Switzerland, February 25, 2026--Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-art syringe for use with its NASHA® lidocaine range of Restylane products in multiple facial indications including the cheeks, nose, chin, jawline, tear troughs, nasolabial folds, marionette lines, as well as in the hands.1-3</description>
</item>
<item>
<title>Galderma Announces Appointment of New Chief Financial Officer</title>
<link>https://6ix.com/company/galderma-group-n/news/galderma-announces-appointment-chief-financial-060000222</link>
<guid isPermaLink="true">https://6ix.com/company/galderma-group-n/news/galderma-announces-appointment-chief-financial-060000222</guid>
<pubDate>Mon, 16 Feb 2026 06:00:00 GMT</pubDate>
<description>ZUG, Switzerland, February 16, 2026--Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced the appointment of Luigi La Corte as Chief Financial Officer (CFO), effective May 1, 2026.</description>
</item>
<item>
<title>We Are All Sculptra: First-of-its-Kind Galderma Initiative to Demonstrate How Everyone Can Benefit from Sculptra’s Regenerative Properties</title>
<link>https://6ix.com/company/galderma-group-n/news/sculptra-first-kind-galderma-initiative-060000077</link>
<guid isPermaLink="true">https://6ix.com/company/galderma-group-n/news/sculptra-first-kind-galderma-initiative-060000077</guid>
<pubDate>Thu, 12 Feb 2026 06:00:00 GMT</pubDate>
<description>ZUG, Switzerland, February 12, 2026--Galderma (SIX: GALD), the pure-play dermatology category leader, today unveiled We Are All Sculptra, a unique program designed to capture the clinical impact of Sculptra® across nine diverse patients – who were all new to injectable aesthetics – over two years.1 This innovative initiative will offer a rare and authentic real-life perspective on the power of regenerative biostimulation to deliver personalized outcomes, and demonstrate how Sculptra adapts to di</description>
</item>
<item>
<title>Galderma Expands Restylane® Portfolio in Japan With Launch of OBT™ Hyaluronic Acid Injectables Restylane Defyne™ and Refyne™</title>
<link>https://6ix.com/company/galderma-group-n/news/galderma-expands-restylane-portfolio-japan-060000047</link>
<guid isPermaLink="true">https://6ix.com/company/galderma-group-n/news/galderma-expands-restylane-portfolio-japan-060000047</guid>
<pubDate>Wed, 11 Feb 2026 06:00:00 GMT</pubDate>
<description>ZUG, Switzerland, February 11, 2026--Galderma (SIX: GALD), the pure-play dermatology category leader, has announced the launch of Restylane Defyne and Restylane Refyne: the first OBT‑based hyaluronic acid injectables ever authorized in Japan.1,2 The products – designed for injection into the mid-to-deep dermis for the correction of moderate to severe facial wrinkles and folds – are now commercially available in the market.1,2</description>
</item>
<item>
<title>Galderma Announces U.S. FDA Acceptance of RelabotulinumtoxinA Biologics License Application Resubmission</title>
<link>https://6ix.com/company/galderma-group-n/news/galderma-announces-u-fda-acceptance-060000079</link>
<guid isPermaLink="true">https://6ix.com/company/galderma-group-n/news/galderma-announces-u-fda-acceptance-060000079</guid>
<pubDate>Mon, 02 Feb 2026 06:00:00 GMT</pubDate>
<description>ZUG, Switzerland, February 02, 2026--Galderma (SIX: GALD) today announced that the U.S. FDA has accepted the BLA resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults. Galderma has worked closely with the U.S. FDA to implement adjustments to its manufacturing process. Galderma is committed to using its expertise and heritage in the neuromodulator space to develop next-generation aes</description>
</item>
<item>
<title>Galderma Tackles Menopause-related Skin Changes With Global Survey and Clinical Trial Inclusivity</title>
<link>https://6ix.com/company/galderma-group-n/news/galderma-tackles-menopause-related-skin-060000949</link>
<guid isPermaLink="true">https://6ix.com/company/galderma-group-n/news/galderma-tackles-menopause-related-skin-060000949</guid>
<pubDate>Fri, 30 Jan 2026 06:00:00 GMT</pubDate>
<description>ZUG, Switzerland, January 30, 2026--Galderma (SIX: GALD) has unveiled findings from a global survey of peri- and post-menopausal women from nine countries exploring the impact of menopause on the skin at the International Master Course on Aging Science (IMCAS) 2026 World Congress in Paris, France, from January 29-31, 2026. The survey found that over 50% of women learned about the effects of menopause on the skin by going through it themselves, with most finding out about it in their 40s.2 Howeve</description>
</item>
<item>
<title>Galderma Unveils ‘Wake Up To Restylane’, Underscoring Restylane as the Ideal Hyaluronic Acid Treatment for Always-On Natural Beauty</title>
<link>https://6ix.com/company/galderma-group-n/news/galderma-unveils-wake-restylane-underscoring-060000865</link>
<guid isPermaLink="true">https://6ix.com/company/galderma-group-n/news/galderma-unveils-wake-restylane-underscoring-060000865</guid>
<pubDate>Thu, 29 Jan 2026 06:00:00 GMT</pubDate>
<description>ZUG, Switzerland, January 29, 2026--Galderma (SIX: GALD), the pure-play dermatology category leader, has launched ‘Wake Up To Restylane’, a global campaign that showcases Restylane as an everyday beauty ally. Aligned with the growing desire for effortless, authentic results that restore facial balance and improve skin quality, the campaign highlights Restylane’s unique ability to deliver personalized results that move naturally with expressions to help people look and feel good.1,6,12-18</description>
</item>
<item>
<title>IMCAS 2026: Galderma Showcases the Latest Scientific Advances Behind the Industry’s Broadest Injectable Aesthetics Portfolio</title>
<link>https://6ix.com/company/galderma-group-n/news/imcas-2026-galderma-showcases-latest-060000833</link>
<guid isPermaLink="true">https://6ix.com/company/galderma-group-n/news/imcas-2026-galderma-showcases-latest-060000833</guid>
<pubDate>Thu, 22 Jan 2026 06:00:00 GMT</pubDate>
<description>ZUG, Switzerland, January 22, 2026--Galderma (SIX: GALD) will present ten posters with the latest updates from across its broad aesthetic portfolio spanning regenerative biostimulation, HA and neuromodulator treatments at the International Master Course on Aging Science (IMCAS) 2026 World Congress in Paris, France, from January 29-31, 2026. The company will also showcase its leadership in community education through a number of events including two symposia, a live anatomy workshop, multiple mas</description>
</item>
<item>
<title>Galderma Provides Update on Arbitration Case Regarding Neuromodulator Research and Development Partnership</title>
<link>https://6ix.com/company/galderma-group-n/news/galderma-provides-arbitration-case-regarding-163500352</link>
<guid isPermaLink="true">https://6ix.com/company/galderma-group-n/news/galderma-provides-arbitration-case-regarding-163500352</guid>
<pubDate>Wed, 21 Jan 2026 16:35:00 GMT</pubDate>
<description>ZUG, Switzerland, January 21, 2026--Galderma (SIX:GALD), the pure-play dermatology category leader, today announced that an International Chamber of Commerce arbitral tribunal issued an award confirming the termination of a 2014 neuromodulator research & development partnership with Ipsen. The partnership was limited to the rights and obligations relating to the companies’ early-stage neuromodulator pipeline for aesthetic indications.</description>
</item>
</channel>
</rss>